Corvus Pharmaceuticals (CRVS) Short Interest Ratio & Short Volume $8.19 -0.33 (-3.87%) (As of 11/15/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Corvus Pharmaceuticals Short Interest DataCorvus Pharmaceuticals (CRVS) has a short interest of 2.93 million shares. This marks a 20.08% increase in short interest from the previous month. The short interest ratio (days to cover) is 4.6, indicating that it would take 4.6 days of the average trading volume of 371,086 shares to cover all short positions.Current Short Interest2,930,000 sharesPrevious Short Interest2,440,000 sharesChange Vs. Previous Month+20.08%Dollar Volume Sold Short$25.90 millionShort Interest Ratio4.6 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares62,550,000 sharesPercentage of Shares Shorted4.68%Today's Trading Volume2,348,992 sharesAverage Trading Volume371,086 sharesToday's Volume Vs. Average633% Short Selling Corvus Pharmaceuticals? Sign up to receive the latest short interest report for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCRVS Short Interest Over TimeCRVS Days to Cover Over TimeCRVS Percentage of Float Shorted Over Time Ad Brownstone ResearchBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.I believe we are about to do it again with this new AI project called Stargate Corvus Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/20242,930,000 shares $25.90 million +20.1%N/A4.6 $8.84 10/15/20242,440,000 shares $16.40 million +13.5%N/A4.6 $6.72 9/30/20242,150,000 shares $11.35 million +31.1%N/A5.4 $5.28 9/15/20241,640,000 shares $8.36 million +14.7%N/A4.5 $5.10 8/31/20241,430,000 shares $6.41 million +4.4%N/A4.9 $4.48 8/15/20241,370,000 shares $5.21 million +19.1%N/A5.3 $3.80 Get the Latest News and Ratings for CRVS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 7/31/20241,150,000 shares $2.96 million -8.0%N/A4.7 $2.57 7/15/20241,250,000 shares $2.50 million -12.6%N/A5.8 $2.00 6/30/20241,430,000 shares $2.60 million -4.7%N/A6.6 $1.82 6/15/20241,500,000 shares $3.06 million -1.3%N/A6.5 $2.04 5/31/20241,520,000 shares $3.28 million +17.8%N/A6.5 $2.16 5/15/20241,290,000 shares $2.86 million -5.2%N/A5.2 $2.22 4/30/20241,360,000 shares $2.11 million -0.7%3.7%5.4 $1.55 4/15/20241,370,000 shares $2.01 million -2.1%3.7%7 $1.47 3/31/20241,400,000 shares $2.49 million -6.0%3.8%6.6 $1.78 3/15/20241,490,000 shares $2.83 million +17.3%4.0%6.8 $1.90 2/29/20241,270,000 shares $2.84 million No Change3.4%5.7 $2.24 2/15/20241,270,000 shares $2.98 million -8.0%3.4%6.2 $2.35 1/31/20241,380,000 shares $2.76 million -1.4%3.7%6.3 $2.00 1/15/20241,400,000 shares $3.28 million +5.3%3.8%6 $2.34 12/31/20231,330,000 shares $2.34 million +2.3%3.6%6.1 $1.76 12/15/20231,300,000 shares $1.99 million -17.2%3.5%6.5 $1.53 11/30/20231,570,000 shares $2.40 million -12.3%4.3%7.9 $1.53 11/15/20231,790,000 shares $2.70 million +4.7%4.9%6.4 $1.51 10/31/20231,710,000 shares $1.93 million -3.4%4.6%6.4 $1.13 10/15/20231,770,000 shares $2.48 million No Change4.8%7.1 $1.40 9/30/20231,770,000 shares $2.58 million -2.8%4.8%6.1 $1.46 9/15/20231,820,000 shares $2.88 million +32.9%4.9%5 $1.58 8/31/20231,370,000 shares $2.90 million +21.2%3.8%2.3 $2.12 8/15/20231,130,000 shares $2.44 million -2.6%3.1%1.8 $2.16 7/31/20231,160,000 shares $2.61 million -17.7%3.4%1.1 $2.25 7/15/20231,410,000 shares $3.47 million +11.9%4.1%1.3 $2.46 6/30/20231,260,000 shares $2.89 million +61.4%3.7%1.1 $2.29 6/15/2023780,600 shares $1.94 million -19.8%2.3%0.7 $2.49 5/31/2023973,100 shares $2.96 million +113.6%2.8%1.1 $3.04 5/15/2023455,500 shares $1.18 million +209.2%1.3%0.6 $2.60 4/30/2023147,300 shares $159,084.00 -38.3%0.4%0.6 $1.08 4/15/2023238,700 shares $248,248.00 +50.8%0.7%1.1 $1.04 3/31/2023158,300 shares $144,053.00 -20.9%0.5%0.8 $0.91 3/15/2023200,200 shares $144,144.00 +16.9%0.6%2.1 $0.72We recommended Nvidia in 2016, now we’re recommending this… (Ad)The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. 2/28/2023171,200 shares $124,976.00 +35.9%0.5%1.4 $0.73 2/15/2023126,000 shares $97,007.40 +13.7%0.4%1 $0.77 1/31/2023110,800 shares $90,856.00 -34.9%0.3%0.8 $0.82 1/15/2023170,100 shares $154,791.00 -3.7%0.5%1.2 $0.91 12/30/2022176,700 shares $150,195.00 +17.3%0.5%1.2 $0.85 12/15/2022150,600 shares $126,353.40 -53.8%0.4%1 $0.84 11/30/2022325,900 shares $303,803.98 +58.1%0.9%2.2 $0.93 11/15/2022206,100 shares $187,963.20 -0.5%0.6%1.3 $0.91 10/31/2022207,100 shares $179,555.70 -12.4%0.6%1 $0.87 10/15/2022236,500 shares $215,215.00 +16.3%0.7%0.9 $0.91 9/30/2022203,300 shares $166,401.05 +1.6%0.6%0.7 $0.82 9/15/2022200,200 shares $191,191.00 +70.8%0.6%0.6 $0.96 8/31/2022117,200 shares $112,336.20 -64.5%0.3%0.4 $0.96 8/15/2022330,500 shares $371,812.50 -75.2%1.0%1.1 $1.13 7/31/20221,330,000 shares $1.17 million +70.1%3.9%4.7 $0.88 7/15/2022782,000 shares $774,962.00 -15.2%2.3%3.2 $0.99 6/30/2022922,500 shares $913,367.25 +306.2%2.7%3.6 $0.99 6/15/2022227,100 shares $224,806.29 +18.5%0.7%0.9 $0.99 5/31/2022191,600 shares $197,348.00 -22.9%0.6%0.8 $1.03 5/15/2022248,600 shares $258,544.00 +28.6%0.7%1 $1.04 4/30/2022193,300 shares $253,223.00 +5.2%0.6%0.8 $1.31 4/15/2022183,800 shares $266,510.00 -14.9%0.5%0.7 $1.45 3/31/2022215,900 shares $354,076.00 +5.2%0.6%0.7 $1.64 3/15/2022205,200 shares $299,592.00 +3.0%0.6%0.6 $1.46 2/28/2022199,200 shares $352,584.00 -41.3%0.6%0.5 $1.77 2/15/2022339,300 shares $692,172.00 +101.5%1.0%0.7 $2.04 1/31/2022168,400 shares $303,120.00 -43.8%0.5%0.3 $1.80 1/15/2022299,500 shares $673,875.00 +34.0%N/A0 $2.25 12/31/2021223,500 shares $538,635.00 -31.2%0.7%0.3 $2.41 12/15/2021324,700 shares $892,925.00 -43.0%1.0%0.2 $2.75 11/30/2021569,200 shares $1.94 million -45.8%1.9%0.1 $3.41 11/15/20211,050,000 shares $3.89 million -42.9%3.5%0.1 $3.70 10/29/20211,840,000 shares $8.34 million +3.4%6.2%0.2 $4.53 10/15/20211,780,000 shares $8.81 million -42.2%6.3%0.2 $4.95 9/30/20213,080,000 shares $14.91 million +318.7%10.9%0.4 $4.84 9/15/2021735,600 shares $1.68 million +45.0%2.5%0.1 $2.29 8/31/2021507,200 shares $1.15 million -48.0%1.8%2.1 $2.26 8/13/2021975,800 shares $1.93 million -22.6%3.5%4.4 $1.98 7/30/20211,260,000 shares $2.63 million +3.3%4.5%5.3 $2.09 7/15/20211,220,000 shares $2.84 million +0.8%3.7%4.1 $2.33 6/30/20211,210,000 shares $3.23 million +7.1%3.7%4.2 $2.67 6/15/20211,130,000 shares $3.10 million -8.9%3.4%3.5 $2.74 5/28/20211,240,000 shares $3.40 million +3.3%3.8%3.4 $2.74 5/14/20211,200,000 shares $2.95 million -9.1%N/A2.1 $2.46 4/30/20211,320,000 shares $3.72 million -1.5%N/A1.4 $2.82 4/15/20211,340,000 shares $3.79 million -7.6%N/A1.5 $2.83 3/31/20211,450,000 shares $4.26 million -8.2%N/A1.6 $2.94 3/15/20211,580,000 shares $5.10 million +24.4%N/A1.8 $3.23 2/26/20211,270,000 shares $4.55 million +2.4%N/A1.5 $3.58 2/12/20211,240,000 shares $4.89 million +0.8%N/A1.8 $3.94We recommended Nvidia in 2016, now we’re recommending this… (Ad)The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. 1/29/20211,230,000 shares $4.54 million No Change5.7%5 $3.69 1/15/20211,230,000 shares $5.08 million +2.5%5.7%6.6 $4.13 12/31/20201,200,000 shares $4.52 million -3.2%5.6%6.8 $3.77 12/15/20201,240,000 shares $4.90 million -10.1%5.8%1.5 $3.95 11/30/20201,380,000 shares $5.56 million -0.7%6.4%1.6 $4.03 11/15/20201,390,000 shares $5.74 million -9.2%6.5%1.6 $4.13 10/30/20201,530,000 shares $6.10 million +2.7%7.1%1.7 $3.99 10/15/20201,490,000 shares $5.96 million +8.8%6.9%1.6 $4.00 9/30/20201,370,000 shares $5.49 million -14.4%6.4%1.3 $4.01 9/15/20201,600,000 shares $6.75 million -1.2%7.5%0.8 $4.22 8/31/20201,620,000 shares $6.14 million +2.5%7.6%0.8 $3.79 8/14/20201,580,000 shares $6.35 million -2.5%7.4%0.8 $4.02 7/31/20201,620,000 shares $6.87 million +25.6%7.6%0.8 $4.24 7/15/20201,290,000 shares $4.91 million +204.1%6.0%0.6 $3.81 6/30/2020424,200 shares $1.15 million +0.3%2.1%0.2 $2.72 6/15/2020422,900 shares $1.31 million +29.0%2.1%3.2 $3.10 5/29/2020327,800 shares $1.20 million -72.5%1.7%2.2 $3.66 5/15/20201,190,000 shares $4.18 million -4.0%6.0%7.9 $3.51 4/30/20201,240,000 shares $3.14 million -1.6%5.4%8 $2.53 4/15/20201,260,000 shares $2.94 million No Change4.8%8.3 $2.33 3/31/20201,260,000 shares $3.38 million +1.0%5.9%7.4 $2.68 3/13/20201,248,100 shares $2.78 million -2.5%5.9%5.9 $2.23 2/28/20201,280,000 shares $2.60 million -3.8%6.0%6.1 $2.03 2/14/20201,330,000 shares $3.72 million +4.7%6.2%6.4 $2.80 1/31/20201,270,000 shares $4.71 million -5.9%6.0%6.3 $3.71 1/15/20201,350,000 shares $6.86 million -1.5%6.3%6.9 $5.08 12/31/20191,370,000 shares $7.96 million +1.5%6.4%7.6 $5.81 CRVS Short Interest - Frequently Asked Questions What is Corvus Pharmaceuticals' current short interest? Short interest is the volume of Corvus Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of October 31st, traders have sold 2,930,000 shares of CRVS short. Learn More on Corvus Pharmaceuticals' current short interest. What is a good short interest ratio for Corvus Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CRVS shares currently have a short interest ratio of 5.0. Learn More on Corvus Pharmaceuticals's short interest ratio. Which institutional investors are shorting Corvus Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Corvus Pharmaceuticals: Wolverine Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Corvus Pharmaceuticals' short interest increasing or decreasing? Corvus Pharmaceuticals saw a increase in short interest in October. As of October 31st, there was short interest totaling 2,930,000 shares, an increase of 20.1% from the previous total of 2,440,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Corvus Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Corvus Pharmaceuticals: Immunome, Inc. (21.37%), Enlivex Therapeutics Ltd. (0.75%), Aytu BioPharma, Inc. (3.24%), Scholar Rock Holding Co. (16.36%), Recursion Pharmaceuticals, Inc. (27.97%), Mirum Pharmaceuticals, Inc. (14.27%), Harmony Biosciences Holdings, Inc. (15.15%), Wave Life Sciences Ltd. (4.47%), Centessa Pharmaceuticals plc (2.69%), Nurix Therapeutics, Inc. (13.35%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Corvus Pharmaceuticals stock? Short selling CRVS is an investing strategy that aims to generate trading profit from Corvus Pharmaceuticals as its price is falling. CRVS shares are trading down $0.33 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Corvus Pharmaceuticals? A short squeeze for Corvus Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CRVS, which in turn drives the price of the stock up even further. How often is Corvus Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CRVS, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies IMNM Short Interest Data ENLV Short Interest Data AYTU Short Interest Data SRRK Short Interest Data RXRX Short Interest Data MIRM Short Interest Data HRMY Short Interest Data WVE Short Interest Data CNTA Short Interest Data NRIX Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CRVS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRVS Stock Alerts